WBI Share Price

Open 0.26 Change Price %
High 0.28 1 Day 0.00 0.00
Low 0.25 1 Week 0.00 0.00
Close 0.28 1 Month 0.00 0.00
Volume 4500 1 Year 0.00 0.00
52 Week High 0.12
52 Week Low 0.08
WBI Important Levels
Resistance 2 0.31
Resistance 1 0.30
Pivot 0.27
Support 1 0.26
Support 2 0.25
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
DDX 0.50 100.00%
OEC 0.02 100.00%
OEC 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
DXE 0.02 100.00%
BVQ 0.02 100.00%
MKR 0.02 100.00%
SBX 0.02 100.00%
SBX 0.02 100.00%
More..
CVE Canada Top Losers Stocks
RGI 0.02 -50.00%
RGI 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
ASL 0.16 -42.86%
ASL 0.16 -42.86%
ASL 0.16 -42.86%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
More..

Welichem Biotech Inc (CVE: WBI)

WBI Technical Analysis 3
As on 19th Jun 2014 WBI Share Price closed @ 0.28 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.33 & Sell for SHORT-TERM with Stoploss of 0.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
WBI Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
WBI Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.welichem.com
WBI Address
WBI
4475 Weyburne Drive
Suite 316
Burnaby, BC V5G 3L1
Canada
Phone: 604-432-1703
Fax: 604-432-1704
WBI Latest News
Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies   PR Newswire (press release)   - 29th Jun 15
Welichem Announces Termination of Asset Purchase Agreement and Update on ...   Canada NewsWire (press release)   - 23rd Jul 14
Dermatological Drugs Market Forecast 2014-2024   MarketWatch   - 22nd Apr 14
Stiefel receives US FDA approval of Sorilux™ Foam, 0.005% for topical ...   PR Newswire (press release)   - 28th Sep 12
Earnings Preview: Eli Lilly & Co   Seeking Alpha   - 24th Jul 12
Earnings Preview: Abbott Laboratories   Seeking Alpha   - 12th Jul 12
Humana, Aetna using voice technology that detects stress, depression in callers   MedCity News   - 31st May 12
Stiefel to acquire WBI-1001 licensing rights from Welichem   News-Medical.net   - 31st May 12
Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to ...   PR Newswire (press release)   - 31st May 12
Canadian biotech firms 'missing the boat' in Asia   Globe and Mail   - 31st Jan 12
Interactive Technical Analysis Chart Welichem Biotech Inc ( WBI CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Welichem Biotech Inc
WBI Business Profile
Welichem Biotech Inc., a development stage biotechnology company, engages in the discovery and development of therapeutic drugs for autoimmune diseases and cancers. Its lead drug candidate, WBI-2100, is in the pre-clinical stage of development to treat various cancerous tumors. The company is developing product candidates through its Symbiochem technology platform. Welichem Biotech Inc. is based in Burnaby, Canada.